Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater

Steven A. Kaplan, John D. McConnell, Claus Roehrborn, Alan G. Meehan, Michael W. Lee, William R. Noble, John W. Kusek, Leroy M. Nyberg

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Purpose: We examined data from the Medical Therapy of Prostatic Symptoms trial to determine the relationship between baseline TPV and the effect of medical therapy in men with LUTS secondary to BPH. Materials and Methods: A total of 3,047 patients with LUTS were randomized to placebo, 4 to 8 mg doxazosin, 5 mg finasteride or the combination of doxazosin and finasteride. Average treatment duration was 4.5 years The primary outcome was time to overall clinical progression of BPH, defined as a confirmed 4 point or greater increase in AUA SS, acute urinary retention, incontinence, renal insufficiency or recurrent urinary tract infection. Secondary outcomes were the need for invasive therapy for BPH, and changes in AUA SS and the maximum urinary flow rate with time. TPV was measured by transrectal ultrasound at baseline and study end. Results: In patients with a small prostate (baseline TPV less than 25 ml) combination therapy was no better than doxazosin alone for decreasing the risk of clinical progression of BPH and need for invasive therapy as well as improving AUA SS and the maximum urinary flow rate. However, in patients with moderate size (25 to less than 40 ml) or enlarged (40 ml or greater) glands combination therapy led to a clinical benefit in these outcomes that was superior to that of doxazosin or finasteride. Conclusions: Combination therapy with doxazosin and finasteride led to a greater decrease in the risk of clinical progression of BPH than either drug alone in patients with LUTS with a baseline TPV of 25 ml or greater.

Original languageEnglish (US)
Pages (from-to)217-220
Number of pages4
JournalJournal of Urology
Volume175
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Doxazosin
Finasteride
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Prostate
Therapeutics
Urinary Retention
Urinary Incontinence
Urinary Tract Infections
Renal Insufficiency
Placebos

Keywords

  • Combination therapy
  • Doxazosin
  • Finasteride
  • Lower urinary tract symptoms
  • Prostate
  • Prostatic hyperplasia

ASJC Scopus subject areas

  • Urology

Cite this

Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater. / Kaplan, Steven A.; McConnell, John D.; Roehrborn, Claus; Meehan, Alan G.; Lee, Michael W.; Noble, William R.; Kusek, John W.; Nyberg, Leroy M.

In: Journal of Urology, Vol. 175, No. 1, 01.2006, p. 217-220.

Research output: Contribution to journalArticle

Kaplan, Steven A. ; McConnell, John D. ; Roehrborn, Claus ; Meehan, Alan G. ; Lee, Michael W. ; Noble, William R. ; Kusek, John W. ; Nyberg, Leroy M. / Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater. In: Journal of Urology. 2006 ; Vol. 175, No. 1. pp. 217-220.
@article{8cff22e8ce4d48c5873054965cdece1b,
title = "Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater",
abstract = "Purpose: We examined data from the Medical Therapy of Prostatic Symptoms trial to determine the relationship between baseline TPV and the effect of medical therapy in men with LUTS secondary to BPH. Materials and Methods: A total of 3,047 patients with LUTS were randomized to placebo, 4 to 8 mg doxazosin, 5 mg finasteride or the combination of doxazosin and finasteride. Average treatment duration was 4.5 years The primary outcome was time to overall clinical progression of BPH, defined as a confirmed 4 point or greater increase in AUA SS, acute urinary retention, incontinence, renal insufficiency or recurrent urinary tract infection. Secondary outcomes were the need for invasive therapy for BPH, and changes in AUA SS and the maximum urinary flow rate with time. TPV was measured by transrectal ultrasound at baseline and study end. Results: In patients with a small prostate (baseline TPV less than 25 ml) combination therapy was no better than doxazosin alone for decreasing the risk of clinical progression of BPH and need for invasive therapy as well as improving AUA SS and the maximum urinary flow rate. However, in patients with moderate size (25 to less than 40 ml) or enlarged (40 ml or greater) glands combination therapy led to a clinical benefit in these outcomes that was superior to that of doxazosin or finasteride. Conclusions: Combination therapy with doxazosin and finasteride led to a greater decrease in the risk of clinical progression of BPH than either drug alone in patients with LUTS with a baseline TPV of 25 ml or greater.",
keywords = "Combination therapy, Doxazosin, Finasteride, Lower urinary tract symptoms, Prostate, Prostatic hyperplasia",
author = "Kaplan, {Steven A.} and McConnell, {John D.} and Claus Roehrborn and Meehan, {Alan G.} and Lee, {Michael W.} and Noble, {William R.} and Kusek, {John W.} and Nyberg, {Leroy M.}",
year = "2006",
month = "1",
doi = "10.1016/S0022-5347(05)00041-8",
language = "English (US)",
volume = "175",
pages = "217--220",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater

AU - Kaplan, Steven A.

AU - McConnell, John D.

AU - Roehrborn, Claus

AU - Meehan, Alan G.

AU - Lee, Michael W.

AU - Noble, William R.

AU - Kusek, John W.

AU - Nyberg, Leroy M.

PY - 2006/1

Y1 - 2006/1

N2 - Purpose: We examined data from the Medical Therapy of Prostatic Symptoms trial to determine the relationship between baseline TPV and the effect of medical therapy in men with LUTS secondary to BPH. Materials and Methods: A total of 3,047 patients with LUTS were randomized to placebo, 4 to 8 mg doxazosin, 5 mg finasteride or the combination of doxazosin and finasteride. Average treatment duration was 4.5 years The primary outcome was time to overall clinical progression of BPH, defined as a confirmed 4 point or greater increase in AUA SS, acute urinary retention, incontinence, renal insufficiency or recurrent urinary tract infection. Secondary outcomes were the need for invasive therapy for BPH, and changes in AUA SS and the maximum urinary flow rate with time. TPV was measured by transrectal ultrasound at baseline and study end. Results: In patients with a small prostate (baseline TPV less than 25 ml) combination therapy was no better than doxazosin alone for decreasing the risk of clinical progression of BPH and need for invasive therapy as well as improving AUA SS and the maximum urinary flow rate. However, in patients with moderate size (25 to less than 40 ml) or enlarged (40 ml or greater) glands combination therapy led to a clinical benefit in these outcomes that was superior to that of doxazosin or finasteride. Conclusions: Combination therapy with doxazosin and finasteride led to a greater decrease in the risk of clinical progression of BPH than either drug alone in patients with LUTS with a baseline TPV of 25 ml or greater.

AB - Purpose: We examined data from the Medical Therapy of Prostatic Symptoms trial to determine the relationship between baseline TPV and the effect of medical therapy in men with LUTS secondary to BPH. Materials and Methods: A total of 3,047 patients with LUTS were randomized to placebo, 4 to 8 mg doxazosin, 5 mg finasteride or the combination of doxazosin and finasteride. Average treatment duration was 4.5 years The primary outcome was time to overall clinical progression of BPH, defined as a confirmed 4 point or greater increase in AUA SS, acute urinary retention, incontinence, renal insufficiency or recurrent urinary tract infection. Secondary outcomes were the need for invasive therapy for BPH, and changes in AUA SS and the maximum urinary flow rate with time. TPV was measured by transrectal ultrasound at baseline and study end. Results: In patients with a small prostate (baseline TPV less than 25 ml) combination therapy was no better than doxazosin alone for decreasing the risk of clinical progression of BPH and need for invasive therapy as well as improving AUA SS and the maximum urinary flow rate. However, in patients with moderate size (25 to less than 40 ml) or enlarged (40 ml or greater) glands combination therapy led to a clinical benefit in these outcomes that was superior to that of doxazosin or finasteride. Conclusions: Combination therapy with doxazosin and finasteride led to a greater decrease in the risk of clinical progression of BPH than either drug alone in patients with LUTS with a baseline TPV of 25 ml or greater.

KW - Combination therapy

KW - Doxazosin

KW - Finasteride

KW - Lower urinary tract symptoms

KW - Prostate

KW - Prostatic hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=29144516614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144516614&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(05)00041-8

DO - 10.1016/S0022-5347(05)00041-8

M3 - Article

C2 - 16406915

AN - SCOPUS:29144516614

VL - 175

SP - 217

EP - 220

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -